| Prev Close: | 10.43 |
|---|---|
| Open: | 10.50 |
| Bid: | 8.30 x 100 |
| Ask: | 10.77 x 200 |
| 1y Target Est: | 26.07 |
| Beta: | 1.81 |
| Next Earnings Date: | 2-Aug-13 |
| Day's Range: | 10.34 - 10.52 |
|---|---|
| 52wk Range: | 9.16 - 14.99 |
| Volume: | 44,150 |
| Avg Vol (3m): | 67,776 |
| Market Cap: | 153.30M |
| P/E (ttm): | N/A |
| EPS (ttm): | -1.43 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ONCOGENEX PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri May 10)
- OncoGenex Loss Lower than ExpectedZacks(Mon May 6)
- OncoGenex Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Fri May 3)
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013CNW Group(Thu May 2)
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013CNW Group(Thu May 2)
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013PR Newswire(Thu May 2)
- ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatemenEDGAR Online(Thu May 2)
- Q1 2013 Oncogenex Pharmaceuticals, Inc. Earnings Release - After Market CloseCCBN(Thu May 2)
- OncoGenex Pharmaceuticals Becomes Oversold (OGXI)at TheStreet(Wed May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerPR Newswire(Wed May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed May 1)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed May 1)
- OncoGenex initiates clincal trial of OGX-427at theflyonthewall.com(Tue Apr 30)
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group(Tue Apr 30)
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group(Tue Apr 30)
Press Releases
- OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013CNW Group(Thu May 2)
- OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic CancerCNW Group(Wed May 1)
- OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for EnrollmentCNW Group(Tue Apr 30)
Must Read
- Exclusive: Bob Lutz, Chinese in bid to buy Fisker Automotive - sourcesReuters(1969-12-31T18:59:59GMT-05:00)
- A closer look at the 3 new game consoles from Microsoft, Nintendo and SonyThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- More than 91,000 litres of oil spilled from derailed Saskatchewan trainThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- U.S. ambassador David Jacobson to join BMO as vice-chairmanThe Canadian Press(1969-12-31T18:59:59GMT-05:00)
- Poll says teens sharing more on social media sites, more trending to TwitterThe Canadian Press(1969-12-31T18:59:59GMT-05:00)